Tag: Tedopi
OSE Immunotherapeutics receives €8.4 million in public funding to support the Phase 3 clinical trial for the registration of the Tedopi® vaccine against lung cancer – 04/10/2024 at 6:00 p.m.
Nantes, France, April 10, 2024, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company has received non-dilutive financing of 8.4 million euros as part…
OSE Immunotherapeutics announces a collaboration agreement with GenDx for the development of a companion diagnostic test associated with Tedopi®, its epitope-based cancer vaccine candidate – 11/21/2023 at 6:00 p.m.
• A development program to support the next pivotal confirmatory phase 3 clinical trial currently being prepared.• A companion diagnostic test to identify HLA-A*02 positive cancer patients eligible for treatment…
Ose Immuno: new US patent protecting Tedopi until 2037
(CercleFinance.com) – OSE Immunotherapeutics announces that the United States Patent and Trademark Office (USPTO) has granted it a new patent protecting Tedopi®, its therapeutic cancer vaccine, for the treatment of…
OSE Immunotherapeutics receives €1.5 million in funding from Bpifrance for the development of a companion diagnostic test associated with Tedopi®, its vaccine against non-small cell lung cancer – 06/20/2023 at 18:00
• Funding of 1.5 million euros from Bpifrance – Regional Direction of Nantes within the framework of the “R&D Innovation Loan” program. • Development of a companion diagnostic test to…
OSE Immuno: end of patient recruitment in the phase 2 clinical trial evaluating Tedopi in advanced pancreatic cancer
By Alexandra Saintpierre Published on 05/24/2023 at 6:19 p.m. (Boursier.com) — OSE Immunotherapeutics SA announces the end…
OSE Immunotherapeutics: end of recruitment for the Tedopi trial – 2023-05-24 at 18:13
(AOF) – OSE Immunotherapeutics SA announces the end of recruitment in the TEDOPaM phase 2 clinical trial, promoted and conducted by the Gercor group, which is evaluating Tedopi in advanced…
OSE Immuno: early access authorization for Tedopi in Spain
(CercleFinance.com) – OSE Immunotherapeutics announces today that AEMPS, the Spanish Medicines Agency, has made available a new early access program which will allow patients to have access to Tedopi® within…
Ose Immunotherapeutics advances with Tedopi in lung cancer, the Stock Exchange applauds
Propelled on the stock market, the Nantes biotech has announced that it has received compassionate access authorizations in three European countries for its therapeutic vaccine candidate Tedopi against non-small cell…
OSE Immunotherapeutics provides an update on Tedopi®, a therapeutic cancer vaccine, a potential new reference treatment in non-small cell lung cancer after failure of immunotherapy – 10/20/2022 at 6:00 p.m.
Nantes, France – October 20, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), provides an update on Tedopi®, an immunotherapy for the activation of specific T lymphocytes…
OSE Immunotherapeutics: new analyzes of Tedopi – 09/05/2022 at 09:30
The results showed that in patients with the HLA-A2+ phenotype with non-small cell lung cancer, overall survival was longer with Tedopi. (Photo credits: Adobe Stock – ) (CercleFinance.com) – OSE…
OSE Immunotherapeutics Presents New Data on Tedopi® in Phase 3 Clinical Trial in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Immune Checkpoint Inhibitor Treatment, at ESMO Conference 2022 – 09/05/2022 at 07:30
Nantes, France – September 5, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of new analyzes on the phase 3 Atalante-1 trial of the…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…